Table 1.

Baseline characteristics of study participants, HIV-CAUSAL Collaboration 1996–2013

	Individuals	Median [IQR] follow-up months	Person years	cART Initiators (%)
CD4 count, cells/mm3
<50	3522	27 [11, 64]	13088.33	2784 (79%)
50 – 100	3061	33[12, 71]	12360.83	2468 (81%)
100 – 200	8641	34[14, 73]	35951.17	7018 (81%)
200 – 350	21807	33[14, 70]	88392.08	15648 (72%)
350 – 500	24553	31[14, 67]	96822	13854 (56%)
>500	34978	30[13, 62]	130709.67	13372 (38%)
HIV-RNA, log10 copies/mL
<4	30596	29[13, 61]	114836.42	12650 (41%)
4–5	43419	32[14, 67]	171358	25928 (60%)
>5	22547	34[14, 71]	91129.67	16566 (73%)
Sex
Male	75049	32[14, 67]	295646.25	43038 (57%)
Female	21513	29[13, 65]	81677.83	12106 (56%)
Age, years
< 35	44698	30[13, 63]	169760.17	23362 (52%)
35 – 50	40154	33[14, 70]	162430.83	23980 (60%)
≥50	11710	32[12, 67]	45133.08	7802 (67%)
Transmission group
Heterosexual	30060	31[14, 67]	117387.58	17814 (59%)
Homo/bi-sexual	39971	35[16, 71]	166591.83	23014 (58%)
Injection drug-use	8201	24[11, 56]	29432.17	3817 (47%)
Other/unknown	18330	26[11, 58]	63912.5	10499 (57%)
Geographical origin
Western Countries	57041	31[13, 67]	224174.75	32765 (57%)
Sub-Saharan Africa	12497	29[13, 62]	44686.75	7453 (60%)
Rest of World	7577	27[13, 55]	25211.42	4054 (54%)
Unknown country	19447	34[15,74]	83251.17	10872 (56%)
Calendar period
1996 – 1998	20317	38 [14, 118]	112796.42	11251 (55%)
1999 – 2000	8940	40[14, 110]	44845.33	5276 (59%)
2001 – 2003	16639	43[16, 98]	77702	9742 (59%)
2004–2013	50666	27 [12,50]	141980.33	28875 (57%)
Overall	96562	31 [13,65]	377324.08	55144 (57%)

cART. Combined antiretroviral therapy; IQR. Interquantile range.